Castle Biosciences, Inc. (CSTL)

Market Cap	660.09M
Revenue (ttm)	250.73M
Net Income (ttm)	-30.80M
Shares Out	27.61M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,566
Open	24.66
Previous Close	24.25
Day's Range	23.78 - 25.10
52-Week Range	9.26 - 26.70
Beta	0.93
Analysts	Strong Buy
Price Target	33.11 (+38.48%)
Earnings Date	May 2, 2024

About CSTL

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with d...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 25, 2019
• Employees: 638
• Stock Exchange: NASDAQ
• Ticker Symbol: CSTL

Financial Performance

In 2023, CSTL's revenue was $219.79 million, an increase of 60.38% compared to the previous year's $137.04 million. Losses were -$57.47 million, -14.41% less than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $33.11, which is an increase of 38.48% from the latest price.

Price Target

$33.11

(38.48% upside)

Analyst Consensus: Strong Buy